Covered recipient · General Payments record
FAHED BITAR
Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$18,180.23
187 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,300.00 | 4 |
| Food and Beverage | $5,112.53 | 178 |
| Consulting Fee | $750.00 | 2 |
| Education | $17.70 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,074.20 | 14 |
| Novartis Pharmaceuticals Corporation | $5,882.95 | 38 |
| Abbott Laboratories | $1,123.00 | 18 |
| ABIOMED | $766.53 | 19 |
| Edwards Lifesciences Corporation | $449.92 | 7 |
| Amgen Inc. | $354.71 | 17 |
| Boston Scientific Corporation | $253.35 | 10 |
| PFIZER INC. | $225.79 | 13 |
| Amarin Pharma Inc. | $178.57 | 6 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $170.26 | 8 |
| Medtronic Vascular, Inc. | $158.67 | 8 |
| SANOFI-AVENTIS U.S. LLC | $111.36 | 7 |
| Janssen Pharmaceuticals, Inc | $71.37 | 4 |
| Teleflex LLC | $65.09 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $64.96 | 3 |
| Kowa Pharmaceuticals America, Inc. | $53.97 | 3 |
| Braemar Manufacturing, LLC | $41.76 | 1 |
| Regeneron Healthcare Solutions, Inc. | $41.71 | 2 |
| AstraZeneca Pharmaceuticals LP | $35.64 | 3 |
| BIOTRONIK INC. | $23.93 | 1 |
| Chiesi USA, Inc. | $21.50 | 1 |
| Vertiflex, Inc. | $10.99 | 1 |
Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FAHED BITAR
NPI 1174728612 · CMS profile ID 325557
Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology
COVINA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FAHED BITAR, NPI 1174728612, CMS profile ID 325557. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). FAHED BITAR, NPI 1174728612, CMS profile ID 325557. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- FAHED BITAR, NPI 1174728612, CMS profile ID 325557, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
187 matching records · $18,180.23 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 187.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5.95 | 09/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926509 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.51 | 09/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685593279 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.75 | 09/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673344931 | CMS |
| Novartis Pharmaceuticals Corporation | $14.81 | 09/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926505 | CMS |
| Amgen Inc. | $22.63 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663235191 | CMS |
| Kowa Pharmaceuticals America, Inc. | $15.16 | 09/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 630256467 | CMS |
| PFIZER INC. | $21.10 | 09/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672923833 | CMS |
| PFIZER INC. | $10.13 | 09/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672990431 | CMS |
| Teleflex LLC | $17.89 | 09/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688677007 | CMS |
| ABIOMED | $13.04 | 09/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676721507 | CMS |
| Abbott Laboratories | $24.29 | 09/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664512507 | CMS |
| Novartis Pharmaceuticals Corporation | $5.97 | 08/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926503 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.15 | 08/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694149369 | CMS |
| Boston Scientific Corporation | $22.57 | 08/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662749383 | CMS |
| ABIOMED | $34.65 | 08/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676721495 | CMS |
| Boston Scientific Corporation | $19.37 | 08/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662749377 | CMS |
| Medtronic Vascular, Inc. | $4.27 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677012971 | CMS |
| E.R. Squibb & Sons, L.L.C. | $500.00 | 08/16/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651243469 | CMS |
| Janssen Pharmaceuticals, Inc | $22.50 | 08/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658335441 | CMS |
| Medtronic Vascular, Inc. | $39.12 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677012985 | CMS |
| Novartis Pharmaceuticals Corporation | $19.23 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926491 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 08/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651243347 | CMS |
| Novartis Pharmaceuticals Corporation | $6.12 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926501 | CMS |
| Amgen Inc. | $14.57 | 08/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663235189 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.55 | 08/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685299873 | CMS |
| BIOTRONIK INC. | $23.93 | 08/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701545405 | CMS |
| Teleflex LLC | $29.16 | 08/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688677009 | CMS |
| ABIOMED | $19.81 | 08/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676721345 | CMS |
| PFIZER INC. | $10.51 | 07/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672394489 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.78 | 07/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694087605 | CMS |
| Novartis Pharmaceuticals Corporation | $6.01 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926499 | CMS |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $11.92 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 625135515 | CMS |
| Amarin Pharma Inc. | $20.00 | 07/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699184649 | CMS |
| Amarin Pharma Inc. | $116.29 | 07/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699187889 | CMS |
| Boston Scientific Corporation | $17.88 | 07/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662749371 | CMS |
| Novartis Pharmaceuticals Corporation | $18.52 | 07/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926497 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.74 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694112693 | CMS |
| Amgen Inc. | $16.19 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663235185 | CMS |
| Novartis Pharmaceuticals Corporation | $5.88 | 07/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926495 | CMS |
| Amgen Inc. | $27.01 | 07/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663235181 | CMS |
| Amgen Inc. | $25.82 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663235179 | CMS |
| Novartis Pharmaceuticals Corporation | $3.71 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926493 | CMS |
| Abbott Laboratories | $21.65 | 07/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664523375 | CMS |
| ABIOMED | $27.80 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676721335 | CMS |
| Novartis Pharmaceuticals Corporation | $36.14 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926479 | CMS |
| Novartis Pharmaceuticals Corporation | $5.89 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926489 | CMS |
| Amgen Inc. | $22.00 | 07/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663235175 | CMS |
| Boston Scientific Corporation | $22.58 | 07/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662749387 | CMS |
| Abbott Laboratories | $23.87 | 07/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664560109 | CMS |
| Novartis Pharmaceuticals Corporation | $5.82 | 07/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658926487 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,372,659.41 | 119 |
| PY2024 | Recipient | $88,784.30 | 8 |
| PY2024 | Principal investigator | $2,456,127.72 | 65 |
| PY2023 | Recipient | $1,782.00 | 4 |
| PY2023 | Principal investigator | $1,385,141.16 | 67 |
| PY2022 | Recipient | $146.00 | 2 |
| PY2022 | Principal investigator | $1,147,808.22 | 159 |
| PY2021 | Recipient | $117,186.47 | 2 |
| PY2021 | Principal investigator | $1,046,387.72 | 200 |
| PY2020 | Recipient | $196.80 | 1 |
| PY2020 | Principal investigator | $840,011.26 | 516 |
| PY2019 | Recipient | $22,855.79 | 2 |
| PY2019 | Principal investigator | $568,169.67 | 95 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
119 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,465.01 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc. | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,775.00 | 12/12/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754532 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,125.00 | 12/03/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754530 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 12/03/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220998016 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,149.24 | 11/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC | A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) | No dispute reported | 06/30/2026 | 1190309568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 11/19/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754518 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $77.00 | 11/19/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754520 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $77.00 | 11/19/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754522 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 11/19/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754524 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,623.00 | 11/19/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $171.00 | 11/19/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754528 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20.16 | 11/15/2025 | Non-covered Recipient Entity FOOTHILL CARDIOLOGY | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308296 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,500.00 | 11/12/2025 | Non-covered Recipient Entity STONY BROOK INTERNISTS | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190313415 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,143.60 | 11/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513627 |
| Principal investigator 1 | Amgen Inc. | $289.18 | 10/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS - COVINA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246651115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 10/20/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $77.00 | 10/20/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $77.00 | 10/20/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754510 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,662.32 | 10/20/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS COVINA | Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) | No dispute reported | 06/30/2026 | 1190310178 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 10/15/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220998014 |
| Principal investigator 1 | Amgen Inc. | $1,509.32 | 10/08/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS - COVINA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246651120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,000.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754500 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,618.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 10/02/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754516 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 09/10/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513533 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $240.00 | 09/05/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513542 |
| Principal investigator 1 | Amgen Inc. | $65,146.93 | 08/29/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS, INC. | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246651152 |
| Principal investigator 1 | ModernaTX, Inc. | $39.52 | 08/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003795 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $119.00 | 08/27/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513538 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $599.40 | 08/26/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754492 |
| Principal investigator 1 | Eli Lilly and Company | $39,240.00 | 08/26/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 | No dispute reported | 06/30/2026 | 1187882704 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,077.60 | 08/20/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513500 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,907.40 | 08/14/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc. | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920320 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 08/06/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513546 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $54.00 | 07/30/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754488 |
| Principal investigator 1 | Amgen Inc. | $35,816.75 | 07/29/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS, INC. | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246651138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754490 |
| Principal investigator 1 | AstraZeneca UK Limited | $19,400.00 | 07/21/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function | No dispute reported | 06/30/2026 | 1185553789 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,155.20 | 07/16/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513496 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,454.28 | 07/15/2025 | Non-covered Recipient Entity STONY BROOK INTERNISTS | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190313417 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,539.68 | 07/15/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190313611 |
| Principal investigator 1 | ModernaTX, Inc. | $830.13 | 06/26/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003761 |
| Principal investigator 1 | ModernaTX, Inc. | $8,791.86 | 06/18/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003747 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,500.00 | 06/02/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190313603 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 05/28/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220998012 |
| Principal investigator 1 | ModernaTX, Inc. | $6,935.76 | 05/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003757 |
| Principal investigator 1 | ModernaTX, Inc. | $22,607.64 | 05/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003759 |
| Principal investigator 1 | ModernaTX, Inc. | $4,383.00 | 05/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003765 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,274.64 | 05/28/2025 | Non-covered Recipient Entity FOOTHILL CARDIOLOGY | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190308292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 05/27/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 05/27/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 05/27/2025 | Non-covered Recipient Entity Flourish Research | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220754486 |
| Principal investigator 1 | Eli Lilly and Company | $312,405.00 | 05/27/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187882548 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,980.25 | 05/21/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513464 |
| Principal investigator 1 | ModernaTX, Inc. | $830.13 | 05/15/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003793 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,516.36 | 05/15/2025 | Non-covered Recipient Entity FOOTHILL CARDIOLOGY | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190308294 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 05/07/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513472 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 05/02/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513437 |
| Principal investigator 1 | Eli Lilly and Company | $165.00 | 04/30/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187891980 |
| Principal investigator 1 | ModernaTX, Inc. | $2,922.00 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003751 |
| Principal investigator 1 | ModernaTX, Inc. | $2,015.52 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003767 |
| Principal investigator 1 | ModernaTX, Inc. | $418.66 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003769 |
| Principal investigator 1 | ModernaTX, Inc. | $7,074.08 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003779 |
| Principal investigator 1 | ModernaTX, Inc. | $4,383.00 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003783 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $338.80 | 04/18/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513491 |
| Principal investigator 1 | Eli Lilly and Company | $9,193.51 | 04/14/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187892610 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $7,293.75 | 04/09/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513484 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $238.00 | 04/04/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513440 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,309.00 | 04/04/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513443 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $60.00 | 04/04/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513449 |
| Principal investigator 1 | ModernaTX, Inc. | $10,466.50 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003743 |
| Principal investigator 1 | ModernaTX, Inc. | $8,259.68 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003749 |
| Principal investigator 1 | ModernaTX, Inc. | $16,071.00 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003755 |
| Principal investigator 1 | ModernaTX, Inc. | $2,082.20 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003775 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $119.00 | 03/19/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513382 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 03/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513342 |
| Principal investigator 1 | ModernaTX, Inc. | $2,082.20 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003745 |
| Principal investigator 1 | ModernaTX, Inc. | $9,465.04 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003753 |
| Principal investigator 1 | ModernaTX, Inc. | $14,610.00 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003763 |
| Principal investigator 1 | ModernaTX, Inc. | $13,815.78 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003771 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $55,357.28 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190313597 |
| Principal investigator 1 | Eli Lilly and Company | $1,775.80 | 02/25/2025 | Non-covered Recipient Entity MEHRDAD KEVIN ARIANI MD | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187884498 |
| Principal investigator 1 | Eli Lilly and Company | $4,360.13 | 02/25/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187891978 |
| Principal investigator 1 | Eli Lilly and Company | $109.80 | 02/25/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187893536 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 02/21/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513358 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,800.00 | 02/12/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513363 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $60.00 | 02/12/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513374 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $49,509.39 | 02/04/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190313609 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $401,701.45 | 02/03/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS COVINA | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190310174 |
| Principal investigator 1 | Eli Lilly and Company | $405.00 | 01/31/2025 | Non-covered Recipient Entity MEHRDAD KEVIN ARIANI MD | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187885718 |
| Principal investigator 1 | Eli Lilly and Company | $2,781.04 | 01/31/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187892014 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26,358.01 | 01/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190313605 |
| Principal investigator 1 | ModernaTX, Inc. | $26,027.50 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003777 |
| Principal investigator 1 | ModernaTX, Inc. | $9,702.16 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003781 |
| Principal investigator 1 | ModernaTX, Inc. | $418.66 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003785 |
| Principal investigator 1 | ModernaTX, Inc. | $16,071.00 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003789 |
| Principal investigator 1 | Eli Lilly and Company | $24.90 | 01/22/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187892016 |
| Principal investigator 1 | ModernaTX, Inc. | $436.80 | 01/22/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003773 |
| Principal investigator 1 | Eli Lilly and Company | $160,197.00 | 01/21/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187891612 |
| Principal investigator 1 | Eli Lilly and Company | $162,260.00 | 01/21/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187892600 |
| Principal investigator 1 | Eli Lilly and Company | $56,867.00 | 01/17/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187890986 |
| Principal investigator 1 | ModernaTX, Inc. | $7,471.17 | 01/16/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003787 |
| Principal investigator 1 | ModernaTX, Inc. | $436.80 | 01/16/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003791 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,971.20 | 01/15/2025 | Non-covered Recipient Entity FOOTHILL CARDIOLOGY | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308298 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $95,120.66 | 01/15/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS COVINA | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190310176 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,073.64 | 01/09/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS COVINA | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190310180 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 01/08/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513319 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 01/08/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513333 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,925.80 | 01/08/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513425 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,938.40 | 01/08/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Covina - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513428 |
| Principal investigator 1 | Eli Lilly and Company | $333,614.00 | 01/07/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187882700 |
| Principal investigator 1 | Eli Lilly and Company | $168.00 | 01/06/2025 | Non-covered Recipient Entity CALIFORNIA ALLERGY AND ASTHMA MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187876573 |
| Principal investigator 1 | Eli Lilly and Company | $125,829.00 | 01/06/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187892772 |